The primary goal of this research project continues to be the elucidation
of the three-dimensional structures of S-Adenosylmethionine (Adomet)
synthetases from a variety of sources, including mutants. This will be
accomplished by determining and analyzing the crystal structures of native
enzymes as well as the structures of the complexes between these enzymes
and substrates (or inhibitors). Finally, the information gained will be
used to understand the functions of this important enzyme. The rational
design of the potential inhibitors of the enzyme will be carried out based
on the three-dimensional structural information.
The structure of AdoMet synthetase crystallized in the hexagonal form has
been determined at 3.0A resolution in the previous grant period. The
current crystallographic R-factor is 0.32; refinement is in progress.
Unfortunately, the complex between the enzyme and its substrates (ATP and
L-methionine) could not be made in the hexagonal form.
The preliminary study suggests that the substrates can be soaked into
crystals in the tetragonal form. Therefore crystal structure analysis of
the tetragonal form is in this proposal. Adequate amounts of AdoMet
synthetase for this research project have been and will be provided by our
collaborator, Dr. G. D. Markham. Crystallization conditions to grow
relatively large tetragonal bipyramidal crystals (~0.7 nm) have been
characterized in the previous grant period. The crystals belong to the
tetragonal system with space group P41212 or P43212 and cell dimensions
a=b=121.1, c=173.2A. Two subunits of the tetrameric enzyme are in a
crystallographic asymmetric unit. The crystals diffract to about 3.5A
resolution using a conventional X-ray generator at room temperature. The
structure is expected to be solved with a molecular replacement method.
In addition to the structure determination of the tetragonal form, the
structures of several mutants will be determined in this grant period.
They are low and high temperature sensitive mutants (metK 501 and 502) and
a mutant in which Cys 90 and Cys 240 residues are replaced with the alanine
residues. Two enzymes from new sources, a monomeric enzyme of metX gene
product of E. coli and the alpha-subunit of the human enzyme, will be
crystallized and their preliminary X-ray studies will be carried out.
No Sub Projects information available for 5R01GM037233-06
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01GM037233-06
Patents
No Patents information available for 5R01GM037233-06
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01GM037233-06
Clinical Studies
No Clinical Studies information available for 5R01GM037233-06
News and More
Related News Releases
No news release information available for 5R01GM037233-06
History
No Historical information available for 5R01GM037233-06
Similar Projects
No Similar Projects information available for 5R01GM037233-06